Full-Time
Director – External Communications
US, Remote
Posted on 8/22/2024
Suvoda
501-1,000 employees
Software solutions for managing clinical trials
Senior
Conshohocken, PA, USA
Position is remote but based in Conshohocken, Pennsylvania.
- Bachelor’s degree in Communications, Marketing, or a related field. Relevant Master’s degree preferred.
- At least 7 years of experience in external communications, public relations, or a related field, preferably within the technology, healthcare or clinical trial industries.
- Proven track record of developing and executing successful communication strategies.
- Intellectual curiosity and ability to approach problems with a learner’s mindset.
- Experience and deep understanding with digital marketing and social media strategies.
- Excellent written and verbal communication skills.
- Ability to work collaboratively with cross-functional teams and manage multiple projects simultaneously.
- Strong analytical skills and the ability to interpret communication metrics.
- Develop and implement external communication strategies to promote Suvoda’s brand, products, and services.
- Develop and hone a deep understanding of Suvoda’s external audiences, market, business priorities, products, and unique value.
- Craft and support the creation of external facing messages.
- Create and distribute content across various channels, including social media, the Suvoda website, blogs, and industry events. Manage content creation with external resources.
- Support Product Marketing with storytelling for priority industry events, including story arc creation, narrative and presentation development, and research.
- Support relationships with social media agencies, including guiding strategy, plans, and posts. Manage employee advocacy.
- Partner with Digital Marketing to monitor and analyze communication metrics to measure the effectiveness of communication strategies.
- Collaborate with internal teams to ensure consistent messaging and branding across all internal and external communications.
- Keep pace with competitor external communications, messaging and positioning.
- Identify, build relationships with, and develop external-facing messengers, including internal staff and external partners.
- Stay up to date on new technologies as well as industry best practices and trends to continuously improve and innovate the company's communication strategies.
Suvoda offers software solutions for managing complex clinical trials, primarily through its Interactive Response Technology (IRT) system. This system helps with patient randomization, drug supply management, and data collection, and is designed to be modular for quick adaptation to various study types, often within four weeks. Operating on a software as a service (SaaS) model, Suvoda provides ongoing support and additional services like virtual trial solutions, which are crucial for remote participation. The company aims to streamline the clinical trial process, ultimately speeding up the introduction of new treatments to the market.
Company Size
501-1,000
Company Stage
Seed
Total Funding
$38.9M
Headquarters
Conshohocken, Pennsylvania
Founded
2012
Simplify's Take
What believers are saying
- AI-driven patient recruitment tools complement Suvoda's existing IRT system.
- Blockchain technology offers potential for secure data management innovations at Suvoda.
- The rise of decentralized trials increases demand for Suvoda's virtual trial solutions.
What critics are saying
- Sofia may face integration challenges with existing clinical trial systems.
- Data privacy concerns with Sofia could lead to legal and financial repercussions.
- Increased competition from AI-driven solutions may challenge Suvoda's market position.
What makes Suvoda unique
- Suvoda offers a modular IRT system for rapid clinical trial implementation.
- Their AI assistant, Sofia, simplifies trial data access through natural language queries.
- Suvoda provides virtual trial solutions, including direct-to-patient shipping, enhancing trial flexibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -2%From many clicks to one query, drug supply managers can more quickly access, analyze, and visualize the trial supply data they need.PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today announced the early adopter launch of Sofia, an artificial intelligence assistant designed to simplify how study teams access and review clinical trial information.Sofia is available on the Suvoda Platform and can be enabled by sponsors looking to provide drug supply managers with efficient access to vital information through an intuitive chat interface, reducing what were once multi-screen, multi-click processes to simple conversations."When creating Sofia, we asked ourselves: What if clinical trial staff had an AI assistant that could alleviate their administrative burdens?" said E.K. Koh, Chief Product Officer at Suvoda. "Sofia became our answer. It's an exciting opportunity to streamline the management of clinical trials."Built with Suvoda's commitment to reliability and security, Sofia brings greater efficiency to clinical trial operations, while adhering to data privacy and other regulatory requirements in clinical research.Sofia's key capabilities include:Streamlines Information Retrieval: Users access trial information through natural language queries that simplify navigation. They can now easily find answers that otherwise would span multiple screens, putting information they need at their fingertips.Users access trial information through natural language queries that simplify navigation. They can now easily find answers that otherwise would span multiple screens, putting information they need at their fingertips
It follows after Suvoda launched its own purpose-built software platform designed to provide a seamless way for drug trial sponsors and sites to manage data across sites.
Der Low-Code- und No-Code-Ansatz beschleunigt den Entwurf und die Bereitstellung von eCOA-Fragebögen, indem er die Erstellung, Lizenzierung und Lokalisierung von Fragebögen aus dem kritischen Pfad nimmt. PHILADELPHIA, 14. November 2024 /PRNewswire/ – Suvoda, ein weltweit tätiges Technologieunternehmen für klinische Studien, das sich auf komplexe Studien in therapeutischen Bereichen wie Onkologie, Zentralnervensystem (ZNS) und seltene Krankheiten spezialisiert hat, gab den Erhalt eines Patents vom US-Patentamt für die Suvoda Questionnaire Definition Language (SQDL) bekannt, die Teil der Softwarearchitektur seines Produkts eCOA (electronic Clinical Outcome Assessment) ist. Das Patent demonstriert die Leistungsfähigkeit von Suvoda eCOA: beschleunigte Erstellung, Übersetzung, Lokalisierung und Bereitstellung von Fragebögen, damit Sponsoren klinischer Studien ihre Studien effizienter durchführen können. Während eCOA traditionell ein Engpass bei der Durchführung klinischer Studien ist, ermöglichen Suvoda eCOA und sein SQDL-Tool den Sponsoren, qualitativ hochwertige Fragebögen in wenigen Stunden statt in Tagen zu liefern
L'approche low-code/no-code accélère la conception et le déploiement des questionnaires eCOA, en éliminant du chemin critique la création des questionnaires, les licences et la localisation. PHILADELPHIE, 14 novembre 2024 /PRNewswire/ -- Suvoda, une société mondiale de technologie d'essais cliniques spécialisée dans les études complexes dans des domaines thérapeutiques tels que l'oncologie, le système nerveux central (SNC) et les maladies rares, a annoncé la réception d'un brevet de l'Office américain des brevets pour le Suvoda Questionnaire Definition Language (SQDL), qui fait partie de l'architecture logicielle de son produit eCOA (évaluation électronique des résultats cliniques). Le brevet démontre la puissance de la solution eCOA de Suvoda : accélération de la création, de la traduction, de la localisation et du déploiement des questionnaires afin que les promoteurs d'essais cliniques puissent lancer leurs études plus efficacement. Alors que l'eCOA est traditionnellement un goulot d'étranglement dans la mise en œuvre des essais cliniques, l'eCOA de Suvoda et son outil SQDL permettent aux promoteurs de fournir des questionnaires de haute qualité en quelques heures, au lieu de quelques jours
El enfoque de código bajo y sin código acelera el diseño y la implementación del cuestionario eCOA, lo que elimina la creación, la concesión de licencias y la localización del cuestionario de la ruta crítica. PHILADELPHIA, 14 de noviembre de 2024 /PRNewswire/ -- Suvoda una empresa global de tecnología de ensayos clínicos especializada en estudios complejos en áreas terapéuticas como oncología, sistema nervioso central (SNC) y enfermedades raras, anunció la recepción de una patente de la Oficina de Patentes de EE.UU. para el Suvoda Questionnaire Definition Language (SQDL), parte de la arquitectura de software de su producto eCOA (evaluación electrónica de resultados clínicos). La patente demuestra el poder de Suvoda eCOA: creación, traducción, localización e implementación aceleradas de cuestionarios para que los patrocinadores de ensayos clínicos puedan lanzar sus estudios de manera más eficiente. Si bien eCOA es tradicionalmente un cuello de botella en la implementación de ensayos clínicos, Suvoda eCOA y su herramienta SQDL permiten a los patrocinadores entregar cuestionarios de alta calidad en cuestión de horas, en lugar de días